Therapeutic cloning

Status and prospects

Zhiming Han, Catherine A. VandeVoort, Keith E. Latham

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Embryonic stem cells (ESCs) offer a new and remarkable potential for treating and curing a wide range of genetic diseases such as diabetes and muscular dystrophy, degenerative diseases such as Parkinson's disease, renal disease and heart disease, and traumatic injury such as spinal cord injury. Therapeutic cloning, wherein patient-specific ESCs can be derived from pre-implantation stage embryos produced by somatic cell nuclear transfer, constitutes one approach of obtaining histocompatible cells for engraftment. Recent improvements in the production of cloned embryos in non-human primate models, combined with advances in the ability to establish human ESC lines and direct their differentiation along specific pathways support the notion that therapeutic cloning may soon be feasible. This review summarizes the status and current feasibility of the approach and the technical hurdles that must be addressed, and discusses the ethical issues that have arisen as a result.

Original languageEnglish (US)
Pages (from-to)392-397
Number of pages6
JournalCurrent Opinion in Molecular Therapeutics
Volume9
Issue number4
StatePublished - Aug 2007

Fingerprint

Embryonic Stem Cells
Organism Cloning
Inborn Genetic Diseases
Muscular Dystrophies
Spinal Cord Injuries
Ethics
Primates
Parkinson Disease
Heart Diseases
Embryonic Structures
Kidney
Cell Line
Wounds and Injuries
Therapeutics
Human Embryonic Stem Cells

Keywords

  • Regenerative medicine
  • Somatic cell nuclear transfer
  • Stem cell
  • Therapeutic cloning

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Han, Z., VandeVoort, C. A., & Latham, K. E. (2007). Therapeutic cloning: Status and prospects. Current Opinion in Molecular Therapeutics, 9(4), 392-397.

Therapeutic cloning : Status and prospects. / Han, Zhiming; VandeVoort, Catherine A.; Latham, Keith E.

In: Current Opinion in Molecular Therapeutics, Vol. 9, No. 4, 08.2007, p. 392-397.

Research output: Contribution to journalArticle

Han, Z, VandeVoort, CA & Latham, KE 2007, 'Therapeutic cloning: Status and prospects', Current Opinion in Molecular Therapeutics, vol. 9, no. 4, pp. 392-397.
Han Z, VandeVoort CA, Latham KE. Therapeutic cloning: Status and prospects. Current Opinion in Molecular Therapeutics. 2007 Aug;9(4):392-397.
Han, Zhiming ; VandeVoort, Catherine A. ; Latham, Keith E. / Therapeutic cloning : Status and prospects. In: Current Opinion in Molecular Therapeutics. 2007 ; Vol. 9, No. 4. pp. 392-397.
@article{12929c7cbe7f435ab6d1ef10cfb3690a,
title = "Therapeutic cloning: Status and prospects",
abstract = "Embryonic stem cells (ESCs) offer a new and remarkable potential for treating and curing a wide range of genetic diseases such as diabetes and muscular dystrophy, degenerative diseases such as Parkinson's disease, renal disease and heart disease, and traumatic injury such as spinal cord injury. Therapeutic cloning, wherein patient-specific ESCs can be derived from pre-implantation stage embryos produced by somatic cell nuclear transfer, constitutes one approach of obtaining histocompatible cells for engraftment. Recent improvements in the production of cloned embryos in non-human primate models, combined with advances in the ability to establish human ESC lines and direct their differentiation along specific pathways support the notion that therapeutic cloning may soon be feasible. This review summarizes the status and current feasibility of the approach and the technical hurdles that must be addressed, and discusses the ethical issues that have arisen as a result.",
keywords = "Regenerative medicine, Somatic cell nuclear transfer, Stem cell, Therapeutic cloning",
author = "Zhiming Han and VandeVoort, {Catherine A.} and Latham, {Keith E.}",
year = "2007",
month = "8",
language = "English (US)",
volume = "9",
pages = "392--397",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - Therapeutic cloning

T2 - Status and prospects

AU - Han, Zhiming

AU - VandeVoort, Catherine A.

AU - Latham, Keith E.

PY - 2007/8

Y1 - 2007/8

N2 - Embryonic stem cells (ESCs) offer a new and remarkable potential for treating and curing a wide range of genetic diseases such as diabetes and muscular dystrophy, degenerative diseases such as Parkinson's disease, renal disease and heart disease, and traumatic injury such as spinal cord injury. Therapeutic cloning, wherein patient-specific ESCs can be derived from pre-implantation stage embryos produced by somatic cell nuclear transfer, constitutes one approach of obtaining histocompatible cells for engraftment. Recent improvements in the production of cloned embryos in non-human primate models, combined with advances in the ability to establish human ESC lines and direct their differentiation along specific pathways support the notion that therapeutic cloning may soon be feasible. This review summarizes the status and current feasibility of the approach and the technical hurdles that must be addressed, and discusses the ethical issues that have arisen as a result.

AB - Embryonic stem cells (ESCs) offer a new and remarkable potential for treating and curing a wide range of genetic diseases such as diabetes and muscular dystrophy, degenerative diseases such as Parkinson's disease, renal disease and heart disease, and traumatic injury such as spinal cord injury. Therapeutic cloning, wherein patient-specific ESCs can be derived from pre-implantation stage embryos produced by somatic cell nuclear transfer, constitutes one approach of obtaining histocompatible cells for engraftment. Recent improvements in the production of cloned embryos in non-human primate models, combined with advances in the ability to establish human ESC lines and direct their differentiation along specific pathways support the notion that therapeutic cloning may soon be feasible. This review summarizes the status and current feasibility of the approach and the technical hurdles that must be addressed, and discusses the ethical issues that have arisen as a result.

KW - Regenerative medicine

KW - Somatic cell nuclear transfer

KW - Stem cell

KW - Therapeutic cloning

UR - http://www.scopus.com/inward/record.url?scp=34547856985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547856985&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 392

EP - 397

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 4

ER -